Mindfulness Meditation for Chronic Pelvic Pain Management (MEMPHIS)

September 18, 2017 updated by: Queen Mary University of London

Mindfulness Meditation Using a Smart-phone Application for Women With Chronic Pelvic Pain

Chronic pelvic pain (CPP) in women is common, painful and disabling and puts much strain on women's lives and the (National Health Service) NHS.

CPP may be related to internal organs, the nervous system or psychological factors and is often difficult to treat. Surgery and drugs have risks and side effects, are expensive and do not help all patients.

Psychological treatments have potential to improve CPP but are not consistently available. Mindfulness meditation teaches people to accept their sensations and emotions in the present moment. This can help to accept pain better, which enables patients to focus on daily activities and improve their quality of life. It has been shown to help in headache, back pain and depression. Usually mindfulness meditation is taught by attending courses for 8 weeks.

The investigators want to find out in a full-scale trial if mindfulness meditation, taught by using a smartphone app, can help CPP patients.

In preparation for this full-scale study the investigators will conduct the MEMPHIS study to answer the following questions:

  • How many patients are willing to participate?
  • How often they use the app?
  • Reasons for not wanting to participate/not using the app -

    - Which health questionnaires are the most useful ones?

  • How many patients will be required for the full-scale trial?

Patients will receive the usual treatment and be divided into three groups

  • using a 60-day mindfulness meditation app,

    -- using comparison app with progressive muscle relaxation but no meditation

  • no app

Patients will complete health questionnaires, may be asked to comment in a focus group and record pain, medication changes, surgery and emergency medical visits

Study Overview

Detailed Description

CPP affects up to 24% women worldwide accounts for 20% of UK gynaecological clinic referrals and has a considerable impact on patients' quality of life and their income. CPP costs the NHS € 3.3bn per year. Despite costly interventions CPP is often resistant to surgical and medical treatment. Multifactorial psychological and somatic causes require a multidimensional approach. Psychological and somatic causes require a multidimensional approach, which is not routinely offered in gynaecology clinics.

Randomized Control Trial (RCT-) evidence suggests that primary inclusion of psychological interventions may be superior to primary surgery. Although psychological treatment is provided across the NHS, mostly in the context of primary care Improving Access to Psychological

Therapies there are problems with capacity, waiting times and overall number of patients being able to access services. Alternatively, patient self-management (PSM) is now recognised as a tool empowering patients to cope better with their condition.

Mindfulness meditation is a potentially valuable PSM tool in CPP.

The investigators conducted a systematic search of literature (07/2013, updated 12/2013) and found no RCTs on mindfulness meditation in CPP. However, two small pilot trials, one in CPP and one in endometriosis patients with promising results.

The investigators decided to undertake a systematic review on the effect of mindfulness meditation and extend the search to other chronic pain conditions (e.g. back pain, headache, fibromyalgia and diabetic neuropathy) because previous systematic reviews had number of limitations, such as not reporting effect size. Two independent reviewers assessed the risk of bias systematically using Review Manager (RevMan) 5.2 software. Out of 472 citations 9 RCTs were finally included. Most studies were of moderate quality; sample sizes were generally small.

Mindfulness meditation had positive effects on depression in chronic pain patients (SMD -0.28; 95%CI -0.53, -0.03; p = 0.03). A trend in reduction of anxiety and affective pain and a trend towards better QUOL, especially the mental health component and better pain acceptance was observed. Only one of the included studies reported the important measure of pain acceptance. If a larger sample size had been available it would have been likely that this and other health outcomes would have shown significant improvements, as was seen in depression (which was studied on n=259 patients), rather than trends. It is the investigators intention to add results to the body of research from a future full-scale trial.

Currently Mindfulness-based treatment is creating lively research interest. Two recent systematic reviews report positive effects on somatisation disorders and psychological stress. Although there is no ongoing study on patients with CPP, other chronic diseases with strong psychological components of depression and anxiety such as COPD and the RFPB-funded pilot study PATHWAYS on Pulmonary Arterial Hypertension are underway.

Of particular interest, due to the similarities in study design to MEMPHIS, is a recently closed pilot study, MIMS (UKCRN ID 13105) that investigated adjustment to multiple sclerosis.

In MIMS meditation teaching was delivered by videoconference. Web-based delivery has also been explored and shown to be feasible for reducing stress, anxiety and depression; both options are lacking the flexibility of a smartphone app, which is being proposed. There is evolving work on care pathways through primary secondary and tertiary levels for patients with CPP and recently mindfulness meditation has been introduced in Dorset, albeit delivered face-to-face. This could be replaced by cheaper and more flexible app-delivered meditation training.

This study will address the knowledge gaps and provide by:

  1. Providing feasibility data for a large multicentre RCT aimed at rigorously testing Mindfulness meditation in CPP
  2. Establishing whether this app could be seamlessly integrated into CPP pathways

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom, E1 1BB
        • Barts Health NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women with diagnosis of organic and non-organic chronic pelvic pain (CPP) for six months or more
  • Age ≥ 18 years
  • Be capable of understanding the information provided, with use of an interpreter if required and being able to understand simple English as is used in the app

Exclusion Criteria:

  • Males
  • Absence of diagnosis of organic and non-organic chronic pelvic pain (CPP)
  • Diagnosis of organic and non-organic chronic pelvic pain (CPP) lasting for less than 3 months
  • Age < 18 years
  • No access to a Personal computer or smart phone
  • Unable to speak / understand English
  • Current users of the app content available to the public

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness: Group A
Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
Active Comparator: Relaxation: Group B
Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
No Intervention: Treatment as usual: Group C
No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of recruitment
Time Frame: 6 months
Length of time it will take to recruit 90 participant from the time recruitment starts
6 months
Patient adherence to app use
Time Frame: first 8 weeks post-randomisation
first 8 weeks post-randomisation

Secondary Outcome Measures

Outcome Measure
Time Frame
Quality of life score-Physical Functioning subscale (as measured by the RAND Short form Health Survey (SF-36)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Quality of life score-Social Functioning subscale (as measured by the RAND Short form Health Survey (SF-36)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Quality of life score-Pain subscale (as measured by the RAND Short form Health Survey (SF-36)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Quality of life score-General Health subscale (as measured by the RAND Short form Health Survey (SF-36)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Depression score as measured by the Hospital Anxiety and Depression Scale (HADS)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Anxiety score (as measured by HADS)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Mindfulness score as measure by the Cognitive and Mindfulness - Revised (CAMS - R) scale
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Pain related disability score (as measured by the Chronic Pain Grade (CPG) disability subscale
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Self efficacy score (as measured by the Pain Self-Efficacy Questionnaire (PSEQ)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Pain acceptance score (as measured Chronic Pain Acceptance Questionnaire (CPAQ-8)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Sexual Health Outcomes score (as measured by Sexual Health Outcomes in Women Questionnaire (SHOW-Q)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation
Subjective outcome score (as measured by Measure Yourself Medical Outcome Profile (MYMOP)
Time Frame: at 60 days, 3 months, and 6 months post-randomisation
at 60 days, 3 months, and 6 months post-randomisation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Elizabeth Ball, PhD, Barts & The London NHS Trust

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

September 28, 2015

First Submitted That Met QC Criteria

March 22, 2016

First Posted (Estimate)

March 28, 2016

Study Record Updates

Last Update Posted (Actual)

September 20, 2017

Last Update Submitted That Met QC Criteria

September 18, 2017

Last Verified

June 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 010817QM
  • 10925965 (Registry Identifier: ISRCTN)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

This is a feasibility study. data will be used to inform design of a full-scale trial.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pelvic Pain

Clinical Trials on Mindfulness meditation

Subscribe